A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2018
At a glance
- Drugs NLG 802 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors NewLink Genetics Corporation
- 09 Nov 2018 Results presented in the NewLink Genetics Corporation media release.
- 09 Nov 2018 According to a NewLink Genetics Corporation media release, results form this trial are being presented today and tomorrow at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington D.C.
- 06 Nov 2018 According to a NewLink Genetics Corporation media release, abstracts relating to results from this trial have been published and are now available on the Society for Immunotherapy of Cancer (SITC) Conference 2018 website.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History